Drug intelligence / Profile preview

FBT103

Development stage: Preclinical
Lead developer: Facio Biotherapies

Overview

FBT103 is a preclinical-stage therapeutic candidate being developed by Facio Biotherapies for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The candidate is designed to target muscle regeneration pathways to promote muscle repair and restore lost muscle function in patients suffering from progressive muscle-weakening diseases. Specific details regarding its molecular structure, modality, and precise biological target have not been publicly disclosed.

Beyond the preview

Go deeper on FBT103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FBT103.

Explore the full profile